We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Waters Corp | NYSE:WAT | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
5.67 | 1.80% | 321.25 | 327.51 | 319.095 | 321.05 | 507,298 | 21:07:22 |
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
13-3668640
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Stock, par value $0.01 per share
|
WAT
|
New York Stock Exchange, Inc.
|
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
|
|
|
|
Page
|
|
|
PART I
|
|
FINANCIAL INFORMATION
|
|
|||
Item 1.
|
|
|
|
3
|
|
|
|
|
|
3
|
|
||
|
|
|
4
|
|
||
|
|
|
5
|
|
||
|
|
|
6
|
|
||
|
|
|
7
|
|
||
|
|
|
8
|
|
||
|
|
|
9
|
|
||
|
|
|
10
|
|
||
Item 2.
|
|
|
|
31
|
|
|
Item 3.
|
|
|
|
42
|
|
|
Item 4.
|
|
|
|
42
|
|
|
PART II
|
|
|
||||
Item 1.
|
|
|
|
43
|
|
|
Item 1A.
|
|
|
|
43
|
|
|
Item 2.
|
|
|
|
44
|
|
|
Item 6.
|
|
|
|
45
|
|
|
|
|
|
46
|
|
|
|
|
|
|||||
|
(In thousands, except per share data)
|
|||||||
ASSETS
|
|
|
|
|||||
Current assets:
|
|
|
||||||
Cash and cash equivalents
|
$ |
339,036
|
$ |
335,715
|
||||
Investments
|
16,720
|
1,429
|
||||||
Accounts receivable, net
|
496,276
|
587,734
|
||||||
Inventories
|
344,009
|
320,551
|
||||||
Other current assets
|
73,386
|
67,062
|
||||||
Total current assets
|
1,269,427
|
1,312,491
|
||||||
Property, plant and equipment, net
|
459,173
|
417,342
|
||||||
Intangible assets, net
|
248,993
|
240,203
|
||||||
Goodwill
|
427,492
|
356,128
|
||||||
Operating lease assets
|
88,619
|
93,358
|
||||||
Other assets
|
154,598
|
137,533
|
||||||
Total assets
|
$ |
2,648,302
|
$ |
2,557,055
|
||||
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
||
Current liabilities:
|
|
|
||||||
Notes payable and debt
|
$ |
150,000
|
$ |
100,366
|
||||
Accounts payable
|
50,325
|
49,001
|
||||||
Accrued employee compensation
|
33,329
|
43,467
|
||||||
Deferred revenue and customer advances
|
213,402
|
176,360
|
||||||
Current operating lease liabilities
|
26,862
|
27,125
|
||||||
Accrued income taxes
|
87,841
|
45,967
|
||||||
Accrued warranty
|
10,113
|
11,964
|
||||||
Other current liabilities
|
125,448
|
137,084
|
||||||
Total current liabilities
|
697,320
|
591,334
|
||||||
Long-term liabilities:
|
|
|
||||||
Long-term debt
|
1,546,159
|
1,580,797
|
||||||
Long-term portion of retirement benefits
|
62,499
|
59,159
|
||||||
Long-term income tax liabilities
|
356,607
|
394,562
|
||||||
Long-term operating lease liabilities
|
63,828
|
66,881
|
||||||
Other long-term liabilities
|
113,631
|
80,603
|
||||||
Total long-term liabilities
|
2,142,724
|
2,182,002
|
||||||
Total liabilities
|
2,840,044
|
2,773,336
|
||||||
Commitments and contingencies (Notes 7, 8 and 12)
|
|
|
||||||
Stockholders’ deficit:
|
|
|
||||||
Preferred stock, par value $0.01 per share, 5,000 shares authorized, none issued at June 27, 2020 and December 31, 2019
|
—
|
—
|
||||||
Common stock, par value $0.01 per share, 400,000 shares authorized, 161,273 and 161,030 shares issued, 61,916 and 62,587 shares outstanding at June 27, 2020 and December 31, 2019, respectively
|
1,613
|
1,610
|
||||||
Additional
paid-in
capital
|
1,959,498
|
1,926,753
|
||||||
Retained earnings
|
6,762,909
|
6,587,403
|
||||||
Treasury stock, at cost, 99,357 and 98,443 shares at June 27, 2020 and December 31, 2019, respectively
|
(8,788,872
|
) |
(8,612,576
|
) | ||||
Accumulated other comprehensive loss
|
(126,890
|
) |
(119,471
|
) | ||||
Total stockholders’ deficit
|
(191,742
|
) |
(216,281
|
) | ||||
Total liabilities and stockholders’ deficit
|
$ |
2,648,302
|
$ |
2,557,055
|
||||
The accompanying notes are an integral part of the interim consolidated financial statements.
|
|
Three Months Ended
|
|||||||
|
June 27, 2020
|
|
June 29, 2019
|
|
||||
|
(In thousands, except per share data)
|
|||||||
Revenues:
|
|
|
||||||
Product sales
|
$ |
314,920
|
$ |
387,265
|
||||
|
|
|
|
|
|
|
|
|
Service sales
|
205,064
|
211,897
|
||||||
Total net sales
|
519,984
|
599,162
|
||||||
Costs and operating expenses:
|
|
|
||||||
Cost of product sales
|
134,802
|
156,975
|
||||||
Cost of service sales
|
78,332
|
92,571
|
||||||
Selling and administrative expenses
|
117,449
|
133,208
|
||||||
Research and development expenses
|
31,155
|
36,490
|
||||||
Purchased intangibles amortization
|
2,618
|
2,264
|
||||||
Litigation provision
|
514
|
—
|
||||||
Total costs and operating expenses
|
364,870
|
421,508
|
||||||
|
|
|
|
|
|
|
|
|
Operating income
|
155,114
|
177,654
|
||||||
Other expense
|
(736
|
) |
(342
|
) | ||||
|
|
|
|
|
|
|
|
|
Interest expense
|
(13,018
|
) |
(11,448
|
) | ||||
Interest income
|
4,003
|
5,871
|
||||||
|
|
|
|
|
|
|
|
|
Income before income taxes
|
145,363
|
171,735
|
||||||
Provision for income taxes
|
22,434
|
27,325
|
||||||
|
|
|
|
|
|
|
|
|
Net income
|
$ |
122,929
|
$ |
144,410
|
||||
|
|
|
|
|
|
|
|
|
Net income per basic common share
|
$ |
1.98
|
$ |
2.09
|
||||
|
|
|
|
|
|
|
|
|
Weighted-average number of basic common shares
|
61,944
|
68,989
|
||||||
|
|
|
|
|
|
|
|
|
Net income per diluted common share
|
$ |
1.98
|
$ |
2.08
|
||||
|
|
|
|
|
|
|
|
|
Weighted-average number of diluted common shares and equivalents
|
62,184
|
69,494
|
|
Six Months Ended
|
|||||||
|
June 27, 2020
|
|
June 29, 2019
|
|
||||
|
(In thousands, except per share data)
|
|||||||
Revenues:
|
|
|
||||||
Product sales
|
$ |
589,103
|
$ |
707,768
|
||||
Service sales
|
395,820
|
405,256
|
||||||
Total net sales
|
984,923
|
1,113,024
|
||||||
Costs and operating expenses:
|
|
|
||||||
Cost of product sales
|
254,641
|
289,365
|
||||||
Cost of service sales
|
169,137
|
181,212
|
||||||
Selling and administrative expenses
|
265,184
|
267,547
|
||||||
Research and development expenses
|
66,144
|
71,550
|
||||||
Purchased intangibles amortization
|
5,243
|
4,545
|
||||||
Litigation provision
|
1,180
|
—
|
||||||
Total costs and operating expenses
|
761,529
|
814,219
|
||||||
Operating income
|
223,394
|
298,805
|
||||||
Other expense
|
(1,110
|
) |
(867
|
) | ||||
Interest expense
|
(27,097
|
) |
(23,011
|
) | ||||
Interest income
|
8,039
|
14,186
|
||||||
Income before income taxes
|
203,226
|
289,113
|
||||||
Provision for income taxes
|
26,735
|
35,717
|
||||||
Net income
|
$ |
176,491
|
$ |
253,396
|
||||
Net income per basic common share
|
$ |
2.84
|
$ |
3.60
|
||||
Weighted-average number of basic common shares
|
62,085
|
70,331
|
||||||
Net income per diluted common share
|
$ |
2.83
|
$ |
3.57
|
||||
Weighted-average number of diluted common shares and equivalents
|
62,404
|
70,904
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
June 27,
2020 |
June 29,
2019 |
June 27,
2020 |
June 29,
2019 |
|||||||||||||
|
(In thousands)
|
(In thousands)
|
||||||||||||||
Net income
|
$ |
122,929
|
$ |
144,410
|
$ |
176,491
|
$ |
253,396
|
||||||||
Other comprehensive income (loss):
|
|
|
|
|
||||||||||||
Foreign currency translation
|
11,587
|
(7,031
|
) |
(7,757
|
) |
491
|
||||||||||
Unrealized gains on investments before income taxes
|
—
|
710
|
—
|
3,054
|
||||||||||||
Income tax expense
|
—
|
(157
|
) |
—
|
(704
|
) | ||||||||||
Unrealized gains on investments, net of tax
|
—
|
553
|
—
|
2,350
|
||||||||||||
Retirement liability adjustment before reclassifications
|
(522
|
) |
(41
|
) |
(226
|
) |
(102
|
) | ||||||||
Amounts reclassified to other income
|
336
|
90
|
676
|
183
|
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Retirement liability adjustment before income taxes
|
(186
|
) |
49
|
450
|
81
|
|||||||||||
Income tax
benefit (
expense
)
|
126
|
(23
|
) |
(112
|
) |
(47
|
) | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Retirement liability adjustment, net of tax
|
(60
|
) |
26
|
338
|
34
|
|||||||||||
Other comprehensive income (loss)
|
11,527
|
(6,452
|
) |
(7,419
|
) |
2,875
|
||||||||||
Comprehensive income
|
$ |
134,456
|
$ |
137,958
|
$ |
169,072
|
$ |
256,271
|
||||||||
|
Six Months Ended
|
|||||||
June 27, 2020
|
June 29, 2019
|
|||||||
|
|
|
|
|||||
(In thousands)
|
||||||||
Cash flows from operating activities:
|
||||||||
Net income
|
$ |
176,491
|
$ |
253,396
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
||||||
Stock-based compensation
|
18,122
|
|
19,255
|
|||||
Deferred income taxes
|
(777
|
)
|
1,632
|
|||||
Depreciation
|
33,220
|
28,704
|
||||||
Amortization of intangibles
|
26,983
|
24,911
|
||||||
Change in operating assets and liabilities:
|
|
|
||||||
Decrease in accounts receivable
|
86,978
|
52,508
|
||||||
Increase in inventories
|
(27,089
|
) |
(62,200
|
) | ||||
Increase in other current assets
|
(14,699
|
) |
(11,627
|
) | ||||
Decrease (increase) in other assets
|
8,238
|
(15,060
|
) | |||||
Increase (decrease) in accounts payable and other current liabilities
|
34,714
|
(10,439
|
) | |||||
Increase in deferred revenue and customer advances
|
37,558
|
54,672
|
||||||
Effect of the 2017 Tax Cuts & Jobs Act
|
—
|
(3,229
|
) | |||||
Decrease in other liabilities
|
(29,293
|
) |
(29,720
|
)
|
||||
Net cash provided by operating activities
|
350,446
|
302,803
|
||||||
Cash flows from investing activities:
|
|
|
||||||
Additions to property, plant, equipment and software capitalization
|
(97,029
|
) |
(65,188
|
) | ||||
Business acquisitions, net of cash acquired
|
(76,664
|
) |
—
|
|||||
Investment in unaffiliated companies
|
(3,350
|
)
|
(4,750
|
) | ||||
Purchases of investments
|
(16,828
|
) |
(35,523
|
) | ||||
Maturities and sales of investments
|
1,536
|
890,524
|
||||||
Net cash (used in) provided by investing activities
|
(192,335
|
) |
785,063
|
|||||
Cash flows from financing activities:
|
|
|
||||||
Proceeds from debt issuances
|
315,000
|
363
|
||||||
Payments on debt
|
(300,366
|
) |
(245
|
) | ||||
Proceeds from stock plans
|
14,739
|
30,129
|
||||||
Purchases of treasury shares
|
(196,297
|
) |
(1,329,635
|
) | ||||
Proceeds from derivative contracts
|
7,558
|
4,654
|
||||||
Net cash used in financing activities
|
(159,366
|
) |
(1,294,734
|
) | ||||
Effect of exchange rate changes on cash and cash equivalents
|
4,576
|
(1,414
|
) | |||||
Increase (decrease) in cash and cash equivalents
|
3,321
|
(208,282
|
) | |||||
Cash and cash equivalents at beginning of period
|
335,715
|
796,280
|
||||||
Cash and cash equivalents at end of period
|
$ |
339,036
|
$ |
587,998
|
||||
Number
of Common Shares |
Common
Stock |
Additional
Paid-In
Capital |
Retained
Earnings |
Treasury
Stock |
Accumulated
Other Comprehensive Loss |
Total
Stockholders’ Equity |
||||||||||||||||||||||
Balance March 30, 2019
|
160,825
|
$ |
1,608
|
$ |
1,872,216
|
$ |
6,104,191
|
$ |
(6,901,629
|
) | $ |
(108,644
|
) | $ |
967,742
|
|||||||||||||
Net income
|
—
|
—
|
—
|
144,410
|
—
|
—
|
144,410
|
|||||||||||||||||||||
Other comprehensive loss
|
—
|
—
|
—
|
—
|
—
|
(6,452
|
) |
(6,452
|
) | |||||||||||||||||||
Issuance of common stock for employees:
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Employee Stock Purchase Plan
|
15
|
—
|
2,498
|
—
|
—
|
—
|
2,498
|
|||||||||||||||||||||
Treasury stock
|
—
|
—
|
—
|
—
|
(561,197
|
) |
—
|
(561,197
|
)
|
|||||||||||||||||||
Stock-based compensation
|
1
|
—
|
9,244
|
—
|
—
|
—
|
9,244
|
|||||||||||||||||||||
Balance June 29, 2019
|
160,841
|
$ |
1,608
|
$ |
1,883,958
|
$ |
6,248,601
|
$ |
(7,462,826
|
) | $ |
(115,096
|
) | $ |
556,245
|
|||||||||||||
Number
of Common Shares |
Common
Stock |
Additional
Paid-In
Capital |
Retained
Earnings |
Treasury
Stock |
Accumulated
Other Comprehensive
Incom
Loss
e
(
)
|
Total
Stockholders’ Deficit |
||||||||||||||||||||||
Balance March 28, 2020
|
161,253
|
$ |
1,613
|
$ |
1,947,626
|
$ |
6,639,980
|
$ |
(8,788,801
|
) | $ |
(138,417
|
) | $ |
(337,999
|
) | ||||||||||||
Net income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
122,929
|
|
|
|
—
|
|
|
|
—
|
|
|
|
122,929
|
|
Other comprehensive income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
11,527
|
|
|
|
11,527
|
|
Issuance of common stock for employees:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee Stock Purchase Plan
|
|
|
12
|
|
|
|
—
|
|
|
|
2,216
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
2,216
|
|
Stock options exercised
|
|
|
6
|
|
|
|
—
|
|
|
|
779
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
779
|
|
Treasury stock
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(71
|
)
|
|
|
—
|
|
|
|
(71
|
)
|
Stock-based compensation
|
|
|
2
|
|
|
|
|
|
|
|
8,877
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
8,877
|
|
Balance June 27, 2020
|
161,273
|
$ |
1,613
|
$ |
1,959,498
|
$ |
6,762,909
|
$ |
(8,788,872
|
) | $ |
(126,890
|
) | $ |
(191,742
|
) | ||||||||||||
Number
of Common Shares |
Common
Stock |
Additional
Paid-In
Capital |
Retained
Earnings |
Treasury
Stock |
Accumulated
Other Comprehensive Income (Loss) |
Total
Stockholders’ Equity |
||||||||||||||||||||||
Balance December 31, 2018
|
160,472
|
$ |
1,605
|
$ |
1,834,741
|
$ |
5,995,205
|
$ |
(6,146,322
|
) | $ |
(117,971
|
) | $ |
1,567,258
|
|||||||||||||
Net income
|
—
|
—
|
—
|
253,396
|
—
|
—
|
253,396
|
|||||||||||||||||||||
Other comprehensive income
|
—
|
—
|
—
|
—
|
—
|
2,875
|
2,875
|
|||||||||||||||||||||
Issuance of common stock for employees:
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Employee Stock Purchase Plan
|
25
|
—
|
4,168
|
—
|
—
|
—
|
4,168
|
|||||||||||||||||||||
Stock options exercised
|
239
|
2
|
26,097
|
—
|
—
|
—
|
26,099
|
|||||||||||||||||||||
Treasury stock
|
—
|
—
|
—
|
—
|
(1,316,504
|
) |
—
|
(1,316,504
|
)
|
|||||||||||||||||||
Stock-based compensation
|
105
|
1
|
18,952
|
—
|
—
|
—
|
18,953
|
|||||||||||||||||||||
Balance June 29, 2019
|
160,841
|
$ |
1,608
|
$ |
1,883,958
|
$ |
6,248,601
|
$ |
(7,462,826
|
) | $ |
(115,096
|
) | $ |
556,245
|
|||||||||||||
Number
of Common Shares |
Common
Stock |
Additional
Paid-In
Capital |
Retained
Earnings |
Treasury
Stock |
Accumulated
Other Comprehensive Loss |
Total
Stockholders’ Deficit |
||||||||||||||||||||||
Balance December 31, 2019
|
161,030
|
$ |
1,610
|
$ |
1,926,753
|
$ |
6,587,403
|
$ |
(8,612,576
|
) | $ |
(119,471
|
) | $ |
(216,281
|
) | ||||||||||||
Net income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
176,491
|
|
|
|
—
|
|
|
|
—
|
|
|
|
176,491
|
|
Adoption of new accounting pronouncement
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(985
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
(985
|
)
|
Other comprehensive loss
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(7,419
|
)
|
|
|
(7,419
|
)
|
Issuance of common stock for employees:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee Stock Purchase Plan
|
|
|
21
|
|
|
|
|
|
|
|
3,952
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
3,952
|
|
Stock options exercised
|
|
|
87
|
|
|
|
1
|
|
|
|
10,904
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
10,905
|
|
Treasury stock
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(176,296
|
)
|
|
|
—
|
|
|
|
(176,296
|
)
|
Stock-based compensation
|
|
|
135
|
|
|
|
2
|
|
|
|
17,889
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
17,891
|
|
Balance June 27, 2020
|
161,273
|
$ |
1,613
|
$ |
1,959,498
|
$ |
6,762,909
|
$ |
(8,788,872
|
) | $ |
(126,890
|
) | $ |
(191,742
|
) | ||||||||||||
Balance at
Beginning
of Period
|
Impact of
CECL
Adoption
|
Additions
|
Deduction
|
Balance at
End of
Period
|
||||||||||||||||
Allowance for Doubtful Accounts
|
|
|
|
|
|
|||||||||||||||
June 27, 2020
|
$ |
9,560
|
$ |
985
|
$ |
6,664
|
$ |
(3,901
|
) | $ |
13,308
|
|||||||||
June 29, 2019
|
$ |
7,663
|
$ |
—
|
$ |
3,793
|
$ |
(3,426
|
) | $ |
8,030
|
Total at
June 27, 2020 |
Quoted Prices
in Active Markets for Identical Assets
(Level 1)
|
Significant
Other Observable Inputs (Level 2) |
Significant
Unobservable Inputs
(Level 3)
|
|||||||||||||
Assets:
|
|
|
|
|
||||||||||||
Time deposits
|
$ |
16,720
|
$ |
—
|
$ |
16,720
|
$ |
—
|
||||||||
Waters 401(k) Restoration Plan assets
|
33,453
|
33,453
|
—
|
—
|
||||||||||||
Foreign currency exchange contracts
|
|
|
366
|
|
|
|
—
|
|
|
|
366
|
|
|
|
—
|
|
Interest rate cross-currency swap agreements
|
4,392
|
—
|
4,392
|
—
|
||||||||||||
Total
|
$ |
54,931
|
$ |
33,453
|
$ |
21,478
|
$ |
—
|
||||||||
|
|
|
|
|
|
|
|
|||||||||
Liabilities:
|
|
|
|
|
||||||||||||
Contingent consideration
|
$ |
2,787
|
$ |
—
|
$ |
—
|
$ |
2,787
|
||||||||
Foreign currency exchange contracts
|
733
|
—
|
733
|
—
|
||||||||||||
Total
|
$ |
3,520
|
$ |
—
|
$ |
733
|
$ |
2,787
|
||||||||
Total at
December 31, 2019 |
Quoted Prices
in Active Markets for Identical Assets
(Level 1)
|
Significant
Other Observable Inputs (Level 2) |
Significant
Unobservable Inputs
(Level 3)
|
|||||||||||||
Assets:
|
|
|
|
|
||||||||||||
Time deposits
|
$ |
1,642
|
$ |
—
|
$ |
1,642
|
$ |
—
|
||||||||
Waters 401(k) Restoration Plan assets
|
30,158
|
30,158
|
—
|
—
|
||||||||||||
Foreign currency exchange contracts
|
16
|
—
|
16
|
—
|
||||||||||||
Interest rate cross-currency swap agreements
|
4,485
|
|
4,485
|
|
||||||||||||
Total
|
$ |
36,301
|
$ |
30,158
|
$ |
6,143
|
$ |
—
|
||||||||
Liabilities:
|
|
|
|
|
||||||||||||
Contingent consideration
|
$ |
2,557
|
$ |
—
|
$ |
—
|
$ |
2,557
|
||||||||
Foreign currency exchange contracts
|
1,028
|
—
|
1,028
|
—
|
||||||||||||
Total
|
$ |
3,585
|
$ |
—
|
$ |
1,028
|
$ |
2,557
|
||||||||
|
June 27, 2020
|
December 31, 2019
|
||||||||||||||
|
Notional Value
|
|
Fair Value
|
|
Notional Value
|
|
Fair Value
|
|
||||||||
Foreign currency exchange contracts:
|
|
|
|
|
||||||||||||
Other current assets
|
$ |
29,735
|
$ |
366
|
$ |
119,576
|
$ |
16
|
||||||||
Other current liabilities
|
$ |
91,393
|
$ |
733
|
$ |
29,495
|
$ |
1,028
|
||||||||
Interest rate cross-currency swap agreements:
|
|
|
|
|
||||||||||||
Other assets
|
$ |
560,000
|
$ |
4,392
|
$ |
560,000
|
$ |
4,485
|
||||||||
Accumulated other comprehensive income
|
|
$ |
(4,392
|
) |
|
$ |
(4,485
|
)
|
Balance at
Beginning of Period |
Accruals for
Warranties |
Settlements
Made |
Balance at
End of Period |
|||||||||||||
Accrued warranty liability:
|
|
|
|
|
||||||||||||
June 27, 2020
|
$ |
11,964
|
$ |
3,577
|
$ |
(5,428
|
) | $ |
10,113
|
|||||||
June 29, 2019
|
$ |
12,300
|
$ |
3,571
|
$ |
(4,288
|
) | $ |
11,583
|
|
June 27, 2020
|
|
June 29, 2019
|
|
||||
Balance at the beginning of the period
|
$ |
213,695
|
$ |
204,257
|
||||
Recognition of revenue included in balance at beginning of the period
|
(141,297
|
) |
(172,949
|
)
|
||||
Revenue deferred during the period, net of revenue recognized
|
195,444
|
229,162
|
||||||
Balance at the end of the period
|
$ |
267,842
|
$ |
260,470
|
||||
|
June 27, 2020
|
|
||
Deferred revenue and customer advances expected to be recognized in:
|
|
|||
One year or less
|
|
$
|
213,402
|
|
13-24
months
|
34,151
|
|||
25 months and beyond
|
20,289
|
|||
Total
|
$ |
267,842
|
||
|
June 27, 2020
|
|||||||||||||||
Amortized
Cost |
Unrealized
Gain |
Unrealized
Loss |
Fair
Value |
|||||||||||||
Time deposits
|
16,720
|
—
|
—
|
16,720
|
||||||||||||
Total
|
$ |
16,720
|
$ |
—
|
$ |
—
|
$ |
16,720
|
||||||||
Amounts included in:
|
|
|
|
|
||||||||||||
Investments
|
16,720
|
—
|
—
|
16,720
|
||||||||||||
Total
|
$ |
16,720
|
$ |
—
|
$ |
—
|
$ |
16,720
|
||||||||
|
December 31, 2019
|
|||||||||||||||
Amortized
Cost |
Unrealized
Gain |
Unrealized
Loss |
Fair
Value |
|||||||||||||
Time deposits
|
1,642
|
—
|
—
|
1,642
|
||||||||||||
Total
|
$ |
1,642
|
$ |
—
|
$ |
—
|
$ |
1,642
|
||||||||
Amounts included in:
|
|
|
|
|
||||||||||||
Cash equivalents
|
$ |
213
|
$ |
—
|
$ |
—
|
$ |
213
|
||||||||
Investments
|
1,429
|
—
|
—
|
1,429
|
||||||||||||
Total
|
$ |
1,642
|
$ |
—
|
$ |
—
|
$ |
1,642
|
||||||||
|
June 27, 2020
|
December 31, 2019
|
||||||
Due in one year or less
|
$ |
16,720
|
$ |
1,642
|
||||
Total
|
$ |
16,720
|
$ |
1,642
|
||||
|
June 27, 2020
|
December 31, 2019
|
||||||
Raw materials
|
$ |
139,452
|
$ |
126,850
|
||||
Work in progress
|
15,878
|
15,457
|
||||||
Finished goods
|
188,679
|
178,244
|
||||||
Total inventories
|
$ |
344,009
|
$ |
320,551
|
||||
Cash
|
$ |
713
|
||
Accounts receivable and current other assets
|
806
|
|||
Inventory
|
669
|
|||
Prepaid and other assets
|
611
|
|||
Property, plant and equipment, net
|
757
|
|||
Operating lease assets
|
847
|
|||
Intangible assets
|
6,960
|
|||
Goodwill
|
71,632
|
|||
Total assets acquired
|
82,995
|
|||
Accrued expenses and other liabilities
|
2,093
|
|||
Total consideration
|
80,902
|
|||
Fair value of minority investment
|
3,525
|
|||
Cash consideration paid
|
$
|
77,377
|
||
|
June 27, 2020
|
December 31, 2019
|
||||||||||||||||||||||
Gross
Carrying Amount |
Accumulated
Amortization |
Weighted-
Average Amortization Period |
Gross
Carrying Amount |
Accumulated
Amortization |
Weighted-
Average Amortization Period |
|||||||||||||||||||
Capitalized software
|
$ |
512,047
|
$ |
356,036
|
5
years
|
$ |
481,986
|
$ |
333,255
|
5
years
|
||||||||||||||
Purchased intangibles
|
207,733
|
156,065
|
11
years
|
200,523
|
151,722
|
11
years
|
||||||||||||||||||
Trademarks and IPR&D
|
13,601
|
—
|
—
|
13,782
|
—
|
—
|
||||||||||||||||||
Licenses
|
5,483
|
5,195
|
6
years
|
5,669
|
5,298
|
6
years
|
||||||||||||||||||
Patents and other intangibles
|
84,453
|
57,028
|
8
years
|
83,035
|
54,517
|
8
years
|
||||||||||||||||||
Total
|
$ |
823,317
|
$ |
574,324
|
7
years
|
$ |
784,995
|
$ |
544,792
|
7
years
|
||||||||||||||
June 27, 2020
|
December 31, 2019
|
|||||||
Foreign subsidiary lines of credit
|
$ |
—
|
$ |
366
|
||||
Senior unsecured notes
-
Series B
-
5.00%, due February 2020
|
—
|
100,000
|
||||||
Senior unsecured notes
-
Series E
-
3.97%, due March 2021
|
50,000
|
—
|
||||||
Senior unsecured notes
-
Series F
-
3.40%, due June 2021
|
100,000
|
—
|
||||||
Total notes payable and debt, current
|
150,000
|
100,366
|
||||||
Senior unsecured notes
-
Series E
-
3.97%, due March 2021
|
—
|
50,000
|
||||||
Senior unsecured notes
-
Series F
-
3.40%, due June 2021
|
—
|
100,000
|
||||||
Senior unsecured notes
-
Series G
-
3.92%, due June 2024
|
50,000
|
50,000
|
||||||
Senior unsecured notes
-
Series H
-
floating rate*, due June 2024
|
50,000
|
50,000
|
||||||
Senior unsecured notes
-
Series I
-
3.13%, due May 2023
|
50,000
|
50,000
|
||||||
Senior unsecured notes
-
Series K
-
3.44%, due May 2026
|
160,000
|
160,000
|
||||||
Senior unsecured notes
-
Series L
-
3.31%, due September 2026
|
200,000
|
200,000
|
||||||
Senior unsecured notes
-
Series M
-
3.53%, due September 2029
|
300,000
|
300,000
|
||||||
Credit agreement
|
740,000
|
625,000
|
||||||
Unamortized debt issuance costs
|
(3,841
|
) |
(4,203
|
)
|
||||
Total long-term debt
|
1,546,159
|
1,580,797
|
||||||
Total debt
|
$ |
1,696,159
|
$ |
1,681,163
|
||||
*
|
Series H senior unsecured notes bear interest at a 3-month LIBOR for that floating rate interest period plus 1.25%. |
June 27, 2020
|
June 29, 2019
|
|||||||
Balance at the beginning of the period
|
$ |
27,790
|
$ |
26,108
|
||||
Net reductions for lapse of statutes taken during the period
|
(252
|
) |
(105
|
) | ||||
Net additions for tax positions taken during the current period
|
536
|
801
|
||||||
Balance at the end of the period
|
$ |
28,074
|
$ |
26,804
|
||||
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
June 27, 2020
|
June 29, 2019
|
June 27, 2020
|
June 29, 2019
|
|||||||||||||
Cost of sales
|
$ |
635
|
$ |
567
|
$ |
1,205
|
$ |
1,142
|
||||||||
Selling and administrative expenses
|
7,352
|
7,402
|
14,725
|
15,527
|
||||||||||||
Research and development expenses
|
939
|
1,345
|
2,192
|
2,586
|
||||||||||||
Total stock-based compensation
|
$ |
8,926
|
$ |
9,314
|
$ |
18,122
|
$ |
19,255
|
||||||||
|
Six Months Ended
|
|||||||
Options Issued and Significant Assumptions Used to Estimate Option Fair Values
|
June 27, 2020
|
June 29, 2019
|
||||||
Options issued in thousands
|
227
|
139
|
||||||
Risk-free interest rate
|
1.4
|
% |
2.5
|
%
|
||||
Expected life in years
|
6
|
5
|
||||||
Expected volatility
|
26.5
|
% |
24.3
|
%
|
||||
Expected dividends
|
—
|
—
|
|
Six Months Ended
|
|||||||
Weighted-Average Exercise Price and Fair Value of Options on the Date of Grant
|
June 27, 2020
|
June 29, 2019
|
||||||
Exercise price
|
$ |
216.08
|
|
$ |
231.30
|
|
||
Fair value
|
$ |
61.70
|
$ |
61.85
|
Number of Shares
|
Exercise Price per Share
|
Weighted-Average
Exercise Price per
Share
|
||||||||||||||||
Outstanding at December 31, 2019
|
1,455
|
$ |
61.63
|
to
|
$ |
238.52
|
$ |
158.61
|
||||||||||
Granted
|
227
|
$ |
203.37
|
to
|
$ |
235.06
|
$ |
216.08
|
||||||||||
Exercised
|
(87
|
) | $ |
61.63
|
to
|
$ |
208.47
|
$ |
125.50
|
|||||||||
Canceled
|
(148
|
) | $ |
128.93
|
to
|
$ |
238.52
|
$ |
172.91
|
|||||||||
Outstanding at June 27, 2020
|
1,447
|
$ |
75.94
|
to
|
$ |
238.52
|
$ |
168.15
|
||||||||||
Shares
|
Weighted-Average
Grant Date Fair
Value per Share
|
|||||||
Unvested at December 31, 2019
|
260
|
$ |
184.70
|
|||||
Granted
|
105
|
$ |
206.73
|
|||||
Vested
|
(86
|
) | $ |
161.84
|
||||
Forfeited
|
(15
|
) | $ |
185.91
|
||||
Unvested at June 27, 2020
|
264
|
$ |
200.84
|
|||||
Six Months Ended
|
||||||||
Performance Stock Units Issued and Significant Assumptions Used to Estimate Fair Values
|
June 27, 2020
|
June 29, 2019
|
||||||
Performance stock units issued (in thousands)
|
58
|
13
|
||||||
Risk-free interest rate
|
1.3
|
% |
2.4
|
%
|
||||
Expected life in years
|
2.9
|
2.8
|
||||||
Expected volatility
|
25.1
|
% |
|
23.5
|
% | |||
Average volatility of peer companies
|
26.1
|
% |
26.2
|
% | ||||
Correlation coefficient
|
36.6
|
% |
34.2
|
% | ||||
Expected dividends
|
—
|
—
|
Shares
|
Weighted-Average
Fair Value per Share |
|||||||
Unvested at December 31, 2019
|
105
|
$ |
233.11
|
|||||
Granted
|
58
|
$ |
190.45
|
|||||
Vested
|
(37
|
) | $ |
184.51
|
||||
Forfeited
|
(24
|
) | $ |
233.31
|
||||
Unvested at June 27, 2020
|
102
|
$ |
226.44
|
|||||
|
Three Months Ended June 27, 2020
|
|||||||||||
Net Income
(Numerator) |
Weighted-
Average Shares (Denominator) |
Per Share
Amount |
||||||||||
Net income per basic common share
|
$ |
122,929
|
61,944
|
$ |
1.98
|
|||||||
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities
|
—
|
240
|
—
|
|||||||||
Net income per diluted common share
|
$ |
122,929
|
62,184
|
$ |
1.98
|
|||||||
|
Three Months Ended June 29, 2019
|
|||||||||||
Net Income
(Numerator) |
Weighted-
Average Shares (Denominator) |
Per Share
Amount |
||||||||||
Net income per basic common share
|
$ |
144,410
|
68,989
|
$ |
2.09
|
|||||||
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities
|
—
|
505
|
(0.01
|
) | ||||||||
Net income per diluted common share
|
$ |
144,410
|
69,494
|
$ |
2.08
|
|||||||
|
Six Months Ended June 27, 2020
|
|||||||||||
Net Income
(Numerator) |
Weighted-
Average Shares (Denominator) |
Per Share
Amount |
||||||||||
Net income per basic common share
|
$ |
176,491
|
62,085
|
$ |
2.84
|
|||||||
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities
|
—
|
319
|
(0.01
|
)
|
||||||||
Net income per diluted common share
|
$ |
176,491
|
62,404
|
$ |
2.83
|
|||||||
|
Six Months Ended June 29, 2019
|
|||||||||||
Net Income
(Numerator) |
Weighted-
Average Shares (Denominator) |
Per Share
Amount |
||||||||||
Net income per basic common share
|
$ |
253,396
|
70,331
|
$ |
3.60
|
|||||||
Effect of dilutive stock option, restricted stock, performance
s
ck unit and restricted stock unit securities
to
|
—
|
573
|
(0.03
|
) | ||||||||
Net income per diluted common share
|
$ |
253,396
|
70,904
|
$ |
3.57
|
|||||||
Currency Translation
|
Unrealized Gain (Loss)
on Retirement Plans |
Accumulated Other
Comprehensive Loss |
||||||||||
Balance at December 31, 2019
|
$ |
(104,066
|
) | $ |
(15,405
|
) | $ |
(119,471
|
) | |||
Other comprehensive income (loss), net of tax
|
(7,757
|
) |
338
|
(7,419
|
) | |||||||
Balance at June 27, 2020
|
$ |
(111,822
|
) | $ |
(15,067
|
) | $ |
(126,890
|
) | |||
|
Three Months Ended
|
|||||||||||||||||||||||
|
June 27, 2020
|
June 29, 2019
|
||||||||||||||||||||||
U.S.
Pension Plans |
U.S. Retiree
Healthcare Plan |
Non-U.S.
Pension Plans |
U.S.
Pension Plans |
U.S. Retiree
Healthcare Plan |
Non-U.S.
Pension Plans |
|||||||||||||||||||
Service cost
|
$ |
—
|
$ |
151
|
$ |
1,095
|
$ |
—
|
$ |
108
|
$ |
1,075
|
||||||||||||
Interest cost
|
—
|
177
|
338
|
10
|
230
|
430
|
||||||||||||||||||
Expected return on plan assets
|
—
|
(220
|
) |
(454
|
) |
—
|
(177
|
) |
(538
|
) | ||||||||||||||
Net amortization:
|
|
|
|
|
|
|
||||||||||||||||||
Prior service credit
|
—
|
(5
|
) |
(41
|
) |
—
|
(5
|
) |
(37
|
) | ||||||||||||||
Net actuarial loss
|
—
|
—
|
382
|
—
|
—
|
132
|
||||||||||||||||||
Net periodic pension cost
|
$ |
—
|
$ |
103
|
$ |
1,320
|
$ |
10
|
$ |
156
|
$ |
1,062
|
||||||||||||
|
Six Months Ended
|
|||||||||||||||||||||||
|
June 27, 2020
|
June 29, 2019
|
||||||||||||||||||||||
U.S.
Pension Plans |
U.S. Retiree
Healthcare Plan |
Non-U.S.
Pension Plans |
U.S.
Pension Plans |
U.S. Retiree
Healthcare Plan |
Non-U.S.
Pension Plans |
|||||||||||||||||||
Service cost
|
$ |
—
|
$ |
302
|
$ |
2,194
|
$ |
—
|
$ |
250
|
$ |
2,157
|
||||||||||||
Interest cost
|
—
|
353
|
683
|
23
|
389
|
864
|
||||||||||||||||||
Expected return on plan assets
|
—
|
(439
|
) |
(910
|
) |
—
|
(354
|
) |
(1,081
|
) | ||||||||||||||
Net amortization:
|
|
|
|
|
|
|
||||||||||||||||||
Prior service credit
|
—
|
(10
|
) |
(81
|
) |
—
|
(10
|
) |
(74
|
) | ||||||||||||||
Net actuarial loss
|
—
|
—
|
767
|
—
|
—
|
267
|
||||||||||||||||||
Net periodic pension cost
|
$ |
—
|
$ |
206
|
$ |
2,653
|
$ |
23
|
$ |
275
|
$ |
2,133
|
||||||||||||
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
June 27, 2020
|
June 29, 2019
|
June 27, 2020
|
June 29, 2019
|
|||||||||||||
Product net sales:
|
|
|
|
|
||||||||||||
Waters instrument systems
|
$ |
181,399
|
$ |
238,777
|
$ |
324,228
|
$ |
423,389
|
||||||||
Chemistry consumables
|
95,105
|
100,292
|
192,350
|
199,545
|
||||||||||||
TA instrument systems
|
38,416
|
48,196
|
72,525
|
84,834
|
||||||||||||
Total product sales
|
314,920
|
387,265
|
589,103
|
707,768
|
||||||||||||
Service net sales:
|
|
|
|
|
||||||||||||
Waters service
|
189,205
|
192,048
|
363,342
|
368,097
|
||||||||||||
TA service
|
15,859
|
19,849
|
32,478
|
37,159
|
||||||||||||
Total service sales
|
205,064
|
211,897
|
395,820
|
405,256
|
||||||||||||
Total net sales
|
$ |
519,984
|
$ |
599,162
|
$ |
984,923
|
$ |
1,113,024
|
||||||||
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
June 27, 2020
|
June 29, 2019
|
June 27, 2020
|
June 29, 2019
|
|||||||||||||
Net Sales:
|
|
|
|
|
||||||||||||
Asia:
|
|
|
|
|
||||||||||||
China
|
$ |
89,816
|
$ |
112,796
|
$ |
137,047
|
$ |
202,887
|
||||||||
Japan
|
41,230
|
45,958
|
86,319
|
89,462
|
||||||||||||
Asia Other
|
77,163
|
80,081
|
143,923
|
146,998
|
||||||||||||
Total Asia
|
208,209
|
238,835
|
367,289
|
439,347
|
||||||||||||
Americas:
|
|
|
|
|
||||||||||||
United States
|
148,928 | 173,940 | 292,826 | 323,097 | ||||||||||||
Americas Other
|
25,854
|
32,835
|
54,132
|
65,546
|
||||||||||||
Total Americas
|
174,782
|
206,775
|
346,958
|
388,643
|
||||||||||||
Europe
|
136,993
|
153,552
|
270,676
|
285,034
|
||||||||||||
Total net sales
|
$ |
519,984
|
$ |
599,162
|
$ |
984,923
|
$ |
1,113,024
|
||||||||
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
June 27, 2020
|
June 29, 2019
|
June 27, 2020
|
June 29, 2019
|
|||||||||||||
Pharmaceutical
|
$ |
311,018
|
$ |
350,145
|
$ |
583,581
|
$ |
644,657
|
||||||||
Industrial
|
152,110
|
176,109
|
295,464
|
331,327
|
||||||||||||
Academic and governmental
|
56,856
|
72,908
|
105,878
|
137,040
|
||||||||||||
Total net sales
|
$ |
519,984
|
$ |
599,162
|
$ |
984,923
|
$ |
1,113,024
|
||||||||
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||
June 27, 2020
|
June 29, 2019
|
June 27, 2020
|
June 29, 2019
|
|||||||||||||
Net sales recognized at a point in time:
|
|
|
|
|
||||||||||||
Instrument systems
|
$ |
219,815
|
$ |
286,973
|
$ |
396,753
|
$ |
508,223
|
||||||||
Chemistry consumables
|
95,105
|
100,292
|
192,350
|
199,545
|
||||||||||||
Service sales recognized at a point in time (time & materials)
|
78,867
|
84,807
|
146,609
|
157,566
|
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total net sales recognized at a point in time
|
393,787
|
472,072
|
735,712
|
865,334
|
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net sales recognized over time:
|
|
|
|
|
||||||||||||
Service and software maintenance sales recognized over time (contracts)
|
126,197
|
127,090
|
249,211
|
247,690
|
||||||||||||
Total net sales
|
$ |
519,984
|
$ |
599,162
|
$ |
984,923
|
$ |
1,113,024
|
||||||||
Three Months Ended
|
Six Months Ended
|
|||||||||||||||||||||||
June 27,
2020 |
June 29,
2019 |
% change
|
June 27,
2020 |
June 29,
2019 |
% change
|
|||||||||||||||||||
Revenues:
|
||||||||||||||||||||||||
Product sales
|
$ | 314,920 | $ | 387,265 |
|
(19
|
%)
|
$ | 589,103 | $ | 707,768 |
|
(17
|
%)
|
||||||||||
Service sales
|
205,064 | 211,897 |
|
(3
|
%)
|
395,820 | 405,256 |
|
(2
|
%)
|
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total net sales
|
519,984 | 599,162 |
|
(13
|
%)
|
984,923 | 1,113,024 |
|
(12
|
%)
|
||||||||||||||
Costs and operating expenses:
|
||||||||||||||||||||||||
Cost of sales
|
213,134 | 249,546 |
|
(15
|
%)
|
423,778 | 470,577 |
|
(10
|
%)
|
||||||||||||||
Selling and administrative expenses
|
117,449 | 133,208 |
|
(12
|
%)
|
265,184 | 267,547 |
|
(1
|
%)
|
||||||||||||||
Research and development expenses
|
31,155 | 36,490 |
|
(15
|
%)
|
66,144 | 71,550 |
|
(8
|
%)
|
||||||||||||||
Purchased intangibles amortization
|
2,618 | 2,264 |
|
16
|
%
|
5,243 | 4,545 |
|
15
|
%
|
||||||||||||||
Litigation provision
|
514 | — |
|
—
|
|
1,180 | — |
|
—
|
|
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Operating income
|
155,114 | 177,654 |
|
(13
|
%)
|
223,394 | 298,805 |
|
(25
|
%)
|
||||||||||||||
Operating income as a % of sales
|
|
29.8
|
%
|
|
29.7
|
%
|
|
22.7
|
%
|
|
26.8
|
%
|
||||||||||||
Other expense
|
(736 | ) | (342 | ) |
|
115
|
%
|
(1,110 | ) | (867 | ) |
|
28
|
%
|
||||||||||
Interest expense, net
|
(9,015 | ) | (5,577 | ) |
|
62
|
%
|
(19,058 | ) | (8,825 | ) |
|
116
|
%
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Income before income taxes
|
145,363 | 171,735 |
|
(15
|
%)
|
203,226 | 289,113 |
|
(30
|
%)
|
||||||||||||||
Provision for income taxes
|
22,434 | 27,325 |
|
(18
|
%)
|
26,735 | 35,717 |
|
(25
|
%)
|
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Net income
|
$ | 122,929 | $ | 144,410 |
|
(15
|
%)
|
$ | 176,491 | $ | 253,396 |
|
(30
|
%)
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Net income per diluted common share
|
$ | 1.98 | $ | 2.08 |
|
(5
|
%)
|
$ | 2.83 | $ | 3.57 |
|
(21
|
%)
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||||||||||
June 27,
2020 |
June 29,
2019 |
%
change |
June 27,
2020 |
June 29,
2019 |
%
change |
|||||||||||||||||||
Net Sales:
|
||||||||||||||||||||||||
Asia:
|
||||||||||||||||||||||||
China
|
$ | 89,816 | $ | 112,796 |
|
(20
|
%)
|
$ | 137,047 | $ | 202,887 |
|
(32
|
%)
|
||||||||||
Japan
|
41,230 | 45,958 |
|
(10
|
%)
|
86,319 | 89,462 |
|
(4
|
%)
|
||||||||||||||
Asia Other
|
77,163 | 80,081 |
|
(4
|
%)
|
143,923 | 146,998 |
|
(2
|
%)
|
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total Asia
|
208,209 | 238,835 |
|
(13
|
%)
|
367,289 | 439,347 |
|
(16
|
%)
|
||||||||||||||
Americas:
|
||||||||||||||||||||||||
United States
|
148,928 | 173,940 |
|
(14
|
%)
|
292,826 | 323,097 |
|
(9
|
%)
|
||||||||||||||
Americas Other
|
25,854 | 32,835 |
|
(21
|
%)
|
54,132 | 65,546 |
|
(17
|
%)
|
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total Americas
|
174,782 | 206,775 |
|
(15
|
%)
|
346,958 | 388,643 |
|
(11
|
%)
|
||||||||||||||
Europe
|
136,993 | 153,552 |
|
(11
|
%)
|
270,676 | 285,034 |
|
(5
|
%)
|
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total net sales
|
$ | 519,984 | $ | 599,162 |
|
(13
|
%)
|
$ | 984,923 | $ | 1,113,024 |
|
(12
|
%)
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
Six Months Ended
|
|||||||||||||||||||||||
June 27,
2020 |
June 29,
2019 |
%
change |
June 27,
2020 |
June 29,
2019 |
%
change |
|||||||||||||||||||
Pharmaceutical
|
$ | 311,018 | $ | 350,145 |
|
(11
|
%)
|
$ | 583,581 | $ | 644,657 |
|
(9
|
%)
|
||||||||||
Industrial
|
152,110 | 176,109 |
|
(14
|
%)
|
295,464 | 331,327 |
|
(11
|
%)
|
||||||||||||||
Academic and governmental
|
56,856 | 72,908 |
|
(22
|
%)
|
105,878 | 137,040 |
|
(23
|
%)
|
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total net sales
|
$ | 519,984 | $ | 599,162 |
|
(13
|
%)
|
$ | 984,923 | $ | 1,113,024 |
|
(12
|
%)
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
||||||||||||||||||||
June 27, 2020
|
% of
Total |
June 29, 2019
|
% of
Total |
% change
|
||||||||||||||||
Waters instrument systems
|
$ | 181,399 |
|
39
|
%
|
$ | 238,777 |
|
45
|
%
|
|
(24
|
%)
|
|||||||
Chemistry consumables
|
95,105 |
|
20
|
%
|
100,292 |
|
19
|
%
|
|
(5
|
%)
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total Waters product sales
|
276,504 |
|
59
|
%
|
339,069 |
|
64
|
%
|
|
(18
|
%)
|
|||||||||
Waters service
|
189,205 |
|
41
|
%
|
192,048 |
|
36
|
%
|
|
(1
|
%)
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total Waters net sales
|
$ | 465,709 |
|
100
|
%
|
$ | 531,117 |
|
100
|
%
|
|
(12
|
%)
|
|||||||
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
||||||||||||||||||||
June 27, 2020
|
% of
Total |
June 29, 2019
|
% of
Total |
% change
|
||||||||||||||||
Waters instrument systems
|
$ | 324,228 |
|
37
|
%
|
$ | 423,389 |
|
43
|
%
|
|
(23
|
%)
|
|||||||
Chemistry consumables
|
192,350 |
|
22
|
%
|
199,545 |
|
20
|
%
|
|
(4
|
%)
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total Waters product sales
|
516,578 |
|
59
|
%
|
622,934 |
|
63
|
%
|
|
(17
|
%)
|
|||||||||
Waters service
|
363,342 |
|
41
|
%
|
368,097 |
|
37
|
%
|
|
(1
|
%)
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total Waters net sales
|
$ | 879,920 |
|
100
|
%
|
$ | 991,031 |
|
100
|
%
|
|
(11
|
%)
|
|||||||
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
||||||||||||||||||||
June 27, 2020
|
% of
Total |
June 29, 2019
|
% of
Total |
% change
|
||||||||||||||||
TA instrument systems
|
$ | 38,416 |
|
71
|
%
|
$ | 48,196 |
|
71
|
%
|
|
(20
|
%)
|
|||||||
TA service
|
15,859 |
|
29
|
%
|
19,849 |
|
29
|
%
|
|
(20
|
%)
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total TA net sales
|
$ | 54,275 |
|
100
|
%
|
$ | 68,045 |
|
100
|
%
|
|
(20
|
%)
|
|||||||
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
||||||||||||||||||||
June 27, 2020
|
% of
Total |
June 29, 2019
|
% of
Total |
% change
|
||||||||||||||||
TA instrument systems
|
$ | 72,525 |
|
69
|
%
|
$ | 84,834 |
|
70
|
%
|
|
(15
|
%)
|
|||||||
TA service
|
32,478 |
|
31
|
%
|
37,159 |
|
30
|
%
|
|
(13
|
%)
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total TA net sales
|
$ | 105,003 |
|
100
|
%
|
$ | 121,993 |
|
100
|
%
|
|
(14
|
%)
|
|||||||
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
||||||||
June 27, 2020
|
June 29, 2019
|
|||||||
Net income
|
$ | 176,491 | $ | 253,396 | ||||
Depreciation and amortization
|
60,203 | 53,615 | ||||||
Stock-based compensation
|
18,122 | 19,255 | ||||||
Deferred income taxes
|
(777 | ) | 1,632 | |||||
Change in accounts receivable
|
86,978 | 52,508 | ||||||
Change in inventories
|
(27,089 | ) | (62,200 | ) | ||||
Change in accounts payable and other current liabilities
|
34,714 | (10,439 | ) | |||||
Change in deferred revenue and customer advances
|
37,558 | 54,672 | ||||||
Effect of the 2017 Tax Cuts & Jobs Act
|
— | (3,229 | ) | |||||
Other changes
|
(35,754 | ) | (56,407 | ) | ||||
|
|
|
|
|||||
Net cash provided by operating activities
|
350,446 | 302,803 | ||||||
Net cash (used in) provided by investing activities
|
(192,335 | ) | 785,063 | |||||
Net cash used in financing activities
|
(159,366 | ) | (1,294,734 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents
|
4,576 | (1,414 | ) | |||||
|
|
|
|
|||||
Increase (decrease) in cash and cash equivalents
|
$ | 3,321 | $ | (208,282 | ) | |||
|
|
|
|
• |
The changes in accounts receivable were primarily attributable to timing of payments made by customers and timing of sales. Days sales outstanding increased to 87 days at June 27, 2020 as compared to 79 days at June 29, 2019.
|
• |
The changes in inventory were primarily attributable to the reduction in the inventory build plan to adjust inventory levels for lower anticipated sales volume due to the
COVID-19
pandemic.
|
• |
The changes in accounts payable and other current liabilities were a result of the timing of payments to vendors, as well as the annual payment of management incentive compensation.
|
• |
Net cash provided from deferred revenue and customer advances results from annual increases in new service contracts as a higher installed base of customers renew annual service contracts.
|
• |
Other changes were attributable to variation in the timing of various provisions, expenditures, prepaid income taxes and accruals in other current assets, other assets and other liabilities.
|
• |
Risks related to the effects of the
COVID-19
pandemic on our business, including: portions of our global workforce being unable to work fully and/or effectively due to working remotely, illness, quarantines, government actions, facility closures or other reasons related to the pandemic, increased risks of cyber attacks resulting from our temporary remote working model, disruptions in our manufacturing capabilities or to our supply chain, volatility and uncertainty in global capital markets limiting our ability to access capital, customers being unable to make timely payment for purchases and volatility in demand for our products.
|
• |
Foreign currency exchange rate fluctuations that could adversely affect translation of the Company’s future sales, financial operating results and the condition of its
non-U.S.
operations, especially when a currency weakens against the U.S. dollar.
|
• |
Current global economic, sovereign and political conditions and uncertainties, particularly regarding the effect of the
COVID-19
pandemic; new or proposed tariffs or trade regulations or changes in the interpretation or enforcement of existing regulations; the U.K. voting to exit the European Union as well as the Chinese government’s ongoing tightening of restrictions on procurement by government-funded customers; the Company’s ability to access capital and maintain liquidity in volatile market conditions; changes in timing and demand for the Company’s products among the Company’s customers and various market sectors or geographies, particularly if they should reduce capital expenditures or are unable to obtain funding, as in the cases of governmental, academic and research institutions; the effect of mergers and acquisitions on customer demand for the Company’s products; and the Company’s ability to sustain and enhance service.
|
• |
Negative industry trends; changes in the competitive landscape as a result of changes in ownership, mergers and continued consolidation among the Company’s competitors; introduction of competing products by other companies and loss of market share; pressures on prices from customers or resulting from competition; regulatory, economic and competitive obstacles to new product introductions; lack of acceptance of new products; expansion of our business in developing markets; spending by certain
end-markets;
ability to obtain alternative sources for components and modules; and the possibility that future sales of new products related to acquisitions, which trigger contingent purchase payments, may exceed the Company’s expectations.
|
• |
Increased regulatory burdens as the Company’s business evolves, especially with respect to the United States Food and Drug Administration and the United States Environmental Protection Agency, among others, as well as regulatory, environmental and logistical obstacles affecting the distribution of the Company’s products, completion of purchase order documentation by our customers and ability of customers to obtain letters of credit or other financing alternatives.
|
• |
Risks associated with lawsuits, particularly involving claims for infringement of patents and other intellectual property rights.
|
• |
The impact and costs incurred from changes in accounting principles and practices; the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates, specifically as it relates to the 2017 Tax Act in the U.S.; shifts in taxable income among jurisdictions with different effective tax rates; and the outcome of and costs associated with ongoing and future tax audit examinations or changes in respective country legislation affecting the Company’s effective rates.
|
Period
|
Total Number
of Shares Purchased (1) |
Average
Price Paid per Share |
Total Number of
Shares Purchased as Part of Publicly Announced Programs |
Maximum Dollar
Value of Shares that May Yet Be Purchased Under the Programs (2) |
||||||||||||||
March 29, 2020 to April 25, 2020
|
— | $ | — | — | $ | 1,524,905 | ||||||||||||
April 26, 2020 to May 23, 2020
|
— | $ | — | — | $ | 1,524,905 | ||||||||||||
May 24, 2020 to June 27, 2020
|
— | $ | — | — | $ | 1,524,905 | ||||||||||||
|
|
|
|
|||||||||||||||
Total
|
— | $ | — | — | $ | 1,524,905 | ||||||||||||
|
|
|
|
(1) |
The Company repurchased less than one thousand shares of common stock at a cost of less than $1 million related to the vesting of restricted stock during the three months ended June 27, 2020.
|
(2) |
In January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock in open market or private transactions over a
two-year
period. This new program replaced the remaining amounts available under the
pre-existing
authorization. During the second quarter of 2020, the Company has temporarily suspended its share repurchases due to the uncertain business conditions caused by the
COVID-19
pandemic.
|
(*) |
This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filing, except to the extent the Company specifically incorporates it by reference.
|
WATERS CORPORATION | ||
/s/ Sherry L. Buck
|
||
Sherry L. Buck
|
||
Senior Vice President and
Chief Financial Officer
|
1 Year Waters Chart |
1 Month Waters Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions